Cognition Therapeutics, Inc.
CGTXCognition Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related degenerative central nervous system and retinal disorders.
Earnings
Next report
Nov 5, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for age-related degenerative central nervous system and retinal disorders. The company's core value proposition centers on its lead product candidate, zervimesine, which utilizes a synaptoprotective mechanism to prevent pathogenic protein oligomers from binding to neuronal receptors, potentially slowing cognitive decline in diseases like Alzheimer's and Dementia with Lewy bodies.
A clinical-stage developer utilizing a differentiated small-molecule approach to synaptoprotection, distinct from the monoclonal antibody therapies currently dominating the Alzheimer's market.
FAQ
- What is Cognition Therapeutics, Inc.'s market cap?
- Cognition Therapeutics, Inc. (CGTX) has a market capitalization of $99.8M and trades on NASDAQ.
- Who are Cognition Therapeutics, Inc.'s competitors?
- Cognition Therapeutics, Inc.'s key competitors include Biogen, Eli Lilly, Cyclerion Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Cognition Therapeutics, Inc. partner with?
- Cognition Therapeutics, Inc.'s notable partners include Alzheimer’s Clinical Trial Consortium, National Institute of Aging.
- Where is Cognition Therapeutics, Inc. headquartered?
- Cognition Therapeutics, Inc. is headquartered in United States of America and employs approximately 25 people. It has been publicly traded since 2021.